Keystone Nano Inc.
This article was originally published in Start Up
Keystone Nano thinks its expertise in nanotechnology can be leveraged to achieve two valuable commercial goals: improving drug delivery and enhancing medical imaging. The company's Molecular Dots are particles that are just 20-30 nanometers wide and resist clumping. As such, they appear to be able to move through the body without disturbing the immune system.
You may also be interested in...
The burgeoning field of nanotechnology is creating hope as well as anxiety in the healthcare industry as researchers look for the best way to use the technology and the FDA grapples to create a policy for regulating products that incorporate the futuristic micro-miniature science. In health care, early focus has been on infection control products.
If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)